$421 Million is the total value of DAFNA Capital Management LLC's 89 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 91.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $20,215,000 | -12.9% | 207,911 | +0.5% | 4.80% | -30.5% |
| MORF | Buy | MORPHIC HOLDING INC | $11,483,000 | +456.9% | 181,467 | +195.2% | 2.72% | +343.6% |
| NRIX | New | NURIX THERAPEUTICS INC | $9,523,000 | – | 306,320 | +100.0% | 2.26% | – |
| AFMD | Buy | AFFIMED N V | $7,830,000 | +53.9% | 989,857 | +13.2% | 1.86% | +22.7% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $7,277,000 | +36.5% | 406,535 | +17.3% | 1.73% | +8.9% |
| RVMD | Buy | REVOLUTION MEDICINES INC | $6,938,000 | +678.7% | 151,231 | +572.1% | 1.65% | +521.1% |
| BHVN | Buy | BIOHAVEN PHARMACEUTICALS HOLD | $6,398,000 | -9.1% | 93,600 | +14.0% | 1.52% | -27.5% |
| KRTX | Buy | KARUNA THERAPEUTICS INC | $5,771,000 | +240.9% | 48,000 | +188.0% | 1.37% | +171.6% |
| PLX | New | PROTALIX BIOTHERAPEUTICS INC | $5,374,000 | – | 1,204,825 | +100.0% | 1.28% | – |
| ACET | Buy | ADICET BIO INC | $5,037,000 | +362.1% | 385,077 | +396.4% | 1.20% | +268.8% |
| HOOK | Buy | HOOKIPA PHARMA INC | $4,619,000 | +66.6% | 343,455 | +37.4% | 1.10% | +32.8% |
| MREO | Buy | MEREO BIOPHARMA GROUP PLCads | $4,211,000 | +76.0% | 1,249,648 | +87.0% | 1.00% | +40.3% |
| RDHL | New | REDHILL BIOPHARMA LTDsponsored ads | $3,337,000 | – | 455,933 | +100.0% | 0.79% | – |
| MRUS | New | MERUS N V | $3,297,000 | – | 157,841 | +100.0% | 0.78% | – |
| FSII | New | FS DEVELOPMENT CORP II | $2,988,000 | – | 300,000 | +100.0% | 0.71% | – |
| HARP | Buy | HARPOON THERAPEUTICS INC | $2,650,000 | +87.4% | 126,663 | +48.8% | 0.63% | +49.4% |
| NTUS | Buy | NATUS MEDICAL INC | $2,450,000 | +42.9% | 95,653 | +11.8% | 0.58% | +13.9% |
| IFRX | New | INFLARX NV | $2,340,000 | – | 600,000 | +100.0% | 0.56% | – |
| ASLN | New | ASLAN PHARMACEUTICALS LTDads | $2,270,000 | – | 677,500 | +100.0% | 0.54% | – |
| ACAD | New | ACADIA PHARMACEUTICALS INC | $2,141,000 | – | 83,000 | +100.0% | 0.51% | – |
| PHAS | Buy | PHASEBIO PHARMACEUTICALS INC | $2,087,000 | +93.8% | 603,042 | +88.1% | 0.50% | +54.7% |
| GMTX | New | GEMINI THERAPEUTICS INC | $2,033,000 | – | 150,000 | +100.0% | 0.48% | – |
| MRSN | Buy | MERSANA THERAPEUTICS INC | $2,011,000 | +53.4% | 124,263 | +152.2% | 0.48% | +22.3% |
| COGT | New | COGENT BIOSCIENCES INC | $1,963,000 | – | 223,554 | +100.0% | 0.47% | – |
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $1,928,000 | -23.2% | 44,926 | +2.3% | 0.46% | -38.8% |
| BWAY | New | BRAINWAY LTDsponsored ads | $1,806,000 | – | 200,000 | +100.0% | 0.43% | – |
| ATHA | Buy | ATHIRA PHARMA INC | $1,684,000 | +197.5% | 91,531 | +453.7% | 0.40% | +138.1% |
| CGEN | Buy | COMPUGEN LTDord | $1,624,000 | +16.4% | 189,002 | +64.1% | 0.38% | -7.2% |
| RCUS | Buy | ARCUS BIOSCIENCES INC | $1,617,000 | +25.5% | 57,600 | +16.1% | 0.38% | +0.3% |
| CBAY | New | CYMABAY THERAPEUTICS INC | $1,533,000 | – | 337,770 | +100.0% | 0.36% | – |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $1,505,000 | – | 58,600 | +100.0% | 0.36% | – |
| INFI | New | INFINITY PHARMACEUTICALS INC | $1,483,000 | – | 459,260 | +100.0% | 0.35% | – |
| KURA | Buy | KURA ONCOLOGY INC | $1,464,000 | +398.0% | 51,800 | +475.6% | 0.35% | +298.9% |
| CFMS | New | CONFORMIS INC | $1,287,000 | – | 1,300,000 | +100.0% | 0.30% | – |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $1,286,000 | +479.3% | 57,500 | +475.0% | 0.30% | +362.1% |
| ALPN | Buy | ALPINE IMMUNE SCIENCES INC | $1,201,000 | -15.8% | 113,302 | +0.1% | 0.28% | -32.8% |
| LRMR | Buy | LARIMAR THERAPEUTICS INC | $1,190,000 | +14.8% | 81,432 | +68.2% | 0.28% | -8.7% |
| TPTX | New | TURNING POINT THERAPEUTICS I | $994,000 | – | 10,509 | +100.0% | 0.24% | – |
| RIGL | New | RIGEL PHARMACEUTICALS INC | $942,000 | – | 275,500 | +100.0% | 0.22% | – |
| GNFT | Buy | GENFIT S Aads | $871,000 | +58.7% | 188,549 | +64.9% | 0.21% | +27.0% |
| TBPH | New | THERAVANCE BIOPHARMA INC | $840,000 | – | 41,165 | +100.0% | 0.20% | – |
| SPPI | New | SPECTRUM PHARMACEUTICALS INC | $644,000 | – | 197,500 | +100.0% | 0.15% | – |
| XFOR | New | X4 PHARMACEUTICALS INC | $602,000 | – | 69,912 | +100.0% | 0.14% | – |
| ISEE | Buy | IVERIC BIO INC | $556,000 | +16.8% | 89,951 | +30.5% | 0.13% | -7.0% |
| NGM | New | NGM BIOPHARMACEUTICALS INC | $291,000 | – | 10,000 | +100.0% | 0.07% | – |
| CNTB | New | CONNECT BIOPHARMA HLDGS LTDads | $148,000 | – | 8,000 | +100.0% | 0.04% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.